Related Experiment Video
Updated: Jul 11, 2026

Evaluating Targeting Accuracy in the Focal Plane for an Ultrasound-guided High-intensity Focused Ultrasound Phased-array System
Published on: March 6, 2019
Take-home message: are we "off target"?
1Prous Science, Barcelona, Spain. journals@prous.com
Abstract:
Targeted anticancer therapies interfere with specific molecules and block the growth and spread of cancer. In the last decade, the concept of targeted drugs has gained much support from the scientific and medical community as a result of positive outcomes in clinical trials with cancer patients. Particularly, the efficacy of tyrosine kinase inhibitors such as imatinib mesylate (Gleevec), gefitinib (Iressa), sorafenib (Nexavar) and sunitinib malate (Sutent) against various cancer types led to their rapid approval and broad clinical use. Nevertheless, many questions and issues concerning targeted therapies remain to be solved, and the presentations at the recent 5th International Symposium on Targeted Anticancer Therapies (TAT), held March 8-10, 2007, in Amsterdam, the Netherlands, have provided insight into such topics as proper target identification and validation, rectification of criteria used for evaluation of targeted agents in preclinical and clinical setting, design of better preclinical models and advantages of phase 0 clinical trials for evaluation of targeted therapies.
Insights
Targeted anticancer therapies show promise by blocking cancer growth. Further research is needed for optimal target identification, validation, and clinical trial design for these innovative treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Targeted anticancer therapies represent a significant advancement in cancer treatment, focusing on specific molecular pathways to inhibit tumor growth and proliferation.
- The success of tyrosine kinase inhibitors (TKIs) like imatinib, gefitinib, sorafenib, and sunitinib in clinical trials has accelerated their adoption in cancer care.
Framework:
- The 5th International Symposium on Targeted Anticancer Therapies (TAT) convened experts to discuss critical issues in the field.
- Key areas of focus included refining methods for target identification and validation.
- Discussions also addressed the need for improved criteria for evaluating targeted agents in preclinical and clinical settings.
Implementation:
- Developing more effective preclinical models is crucial for accurately assessing drug efficacy and toxicity.
- The symposium highlighted the potential benefits of early-phase (Phase 0) clinical trials for evaluating targeted therapies.
Implications:
- Addressing these challenges will optimize the development and application of targeted anticancer drugs.
- Advancements in preclinical models and clinical trial design are essential for maximizing the clinical benefit of targeted therapies.
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Errors in Global Positioning System
Accuracy and Precision
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Simpson's Rule II
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

